• Biomolecules & Therapeutics
• /
• v.1 no.2
• /
• pp.236-243
• /
• 1993

Immunologic potential of DA-125, a new anthracycline antitumor antibiotic, was investigated using guinea pigs and mice. In antigenicity experiments, guinea pigs were sensitized subcutaneously with DA-125 or DA-125 incorporated in complete Freund's adjuvant (CFA) once a week for three weeks. No systemic anaphylaxis was induced by intravenous injection of DA-125 or DA-125 incubated with guinea pig serum after 3 weeks from the last sensitization. None of sera of these animals showed any passive cutaneous anaphylactic reaction (PCA) when DA-125 or DA-125 incubated with guinea pig serum was used as a challenging antigen in homologous PCA experiment. On the other hand the treatment of guinea pigs with ovalbumin Incorporated in CFA induced systemic anaphylactic reaction when challenged by intravenous injection of 5 mg/body of ovalbumin. Immunodiffusion test revealed no precipitating antibodies as detected in guinea pigs sensitized with DA-125. In 24-hour heterologous PCA reaction with sera of C57BL/6 mice immunized with DA-125 or DA-125 mixed with aluminum hydroxide gel (Alum), None of sera showed positive reaction when DA-125 or DA-125 incubated with rat serum was used as a challenging antigen. Sera of animals immunized with a mixture of ovalbumin and alum showed positive PCA reaction when 5 mg/body of ovalbumin was injected as a challenging antigen. In lymphocyte proliferation tests, spleen lymphocyte proliferation to PHA and LPS was similarly impaired by 12 mg/kg of DXR or 36 mg/kg of DA-125, and the immunodepressive activity of DA-125 showed a dose-dependent manner. From these results, it could be concluded that immunosupression of DA-125 would be comparable to that of DXR and that DA-125 would not induce systemic allergic reaction in its clinical use.

• Korean Journal of Pharmacognosy
• /
• v.41 no.2
• /
• pp.115-121
• /
• 2010

The present study was designed to explore an immunostimulating activity of crude extracts of Macrolepiota procera, and a combination therapy of cisplatin and Macrolepiota procera extracts which can potentiate the anti-cancer activity of cisplatin. For these, water extraction of Macrolepiota procera were performed at $4^{\circ}C$(MPE-4) and $100^{\circ}C$(MPE-100). In experimental metastasis of colon26-M3.1 cells, prophylactic intravenous administration of MPE ($80-2,000{\mu}g$/mouse) inhibited tumor metastasis compared with tumor control. Peritoneal macrophages stimulated with MPE produced IL-12 as well as induced tumoricidal activity. In an analysis of NK-cell activity, i.v. administration of MPE ($200{\mu}g$/mouse) significantly augmented NK cytotoxicity to YAC-1 tumor cells. The combination treatments of cisplatin ($20{\mu}g$) and MPE ($100{\mu}g$) exhibited prolongation of lifespan in colon26-M3.1 tumor bearing mouse. These results suggested that MPE stimulate immune system non-specifically and application as adjuvant in cancer treatment.

• Korean Journal of Veterinary Research
• /
• v.48 no.4
• /
• pp.393-399
• /
• 2008

We investigated the potential of fucoidan for its ability to provide protection from gamma rayinduced damage. In our results, the fucoidan significantly improved the counts of endogenous colony forming unit to $9.5 {\pm} 1.5$, from $5.5 {\pm} 2.5$ compared with un-treated irradiated control group at 10 day after 7 Gy whole body irradiation. After 2 Gy irradiation, fucoidan treatment attenuated the percent of tail DNA of splenocytes, parameters of DNA damage, from $30.17 {\pm} 1.7%$ to $13.67 {\pm} 2.81%$ 2.81% by comet assay and also accelerated the proliferation of splenocytes, compared with un-treated irradiated control group by 3Hthymidine incorporation assay. Furthermore, fucoidan decreased the number of apoptotic fragments per intestinal crypt by 31.8% at 1 days after 2 Gy irradiation. These results indicated that the fucoidan significantly improved the hematopoietic recovery, prevented the DNA damage in immune cells and enhanced their proliferation, which had been suppressed by ionizing radiation. in addition, fucoidan rescued intestinal cells from radiation-induced apoptosis. Thus, this study raises the possibility of using fucoidan as adjuvant therapeutic agent after radiotherapy.

• The Korean Journal of Pain
• /
• v.10 no.1
• /
• pp.21-27
• /
• 1997

Background : Previous studies have proven beneficial in labor analgesia to use subarachnoid sufentanil(alone or with adjuvant) on parturients in early first stage of labor. We designed this prospective study to evaluate analgesic efficacy and side effects of subarachnoid sufentanil plus bupivacaine in women with cervical dilatation of 7 cm greater. Methods : This was an open-label, nonrandomized trial of 32 parturients in late first stage labor who requested labor analgesia. After signing the consent form each patient received subarachnoid sufentanil (10 ${\mu}g$) and bupivacaine (2.5 mg). Patients were asked to rate their verbal pain score (0-10 scale) before regional anesthesia and 5 minutes after subarachnoid injection, and every 20 minutes thereafter until delivery or request for additional analgesia. Blood pressure, pruritus, Bromage motor block score, mode of delivery and need for supplemental analgesics were recorded. Results : Thirty women were included in the study. Mean pain scores (mean${\pm}$SD) were $8.7{\pm}1.0$ pre-spinal, $0.7{\pm}1.5$ 5 minutes post-injection, and remained less than 5 for 130 minutes after spinal injection. Of 30 patients, 24 had unassisted vaginal delivery, 4 instrumental vaginal delivery (vacuum), and 2 cesarean delivery. Of 28 patients who delivered vaginally, 19 did not require supplemental analgesics and had a delivery pain score of 5 or lower. Blood pressure decreased in three patients after spinal analgesia (p<0.05), which necessitated treatment. The Bromage motor block score was 0 in 26 patients and 1 in 4 patients. Pruritus was noted in 22 patients. Conclusion : Subarachnoid sufentanil-bupivacaine provides rapid analgesia for an effective duration of approximately 130 minutes in parturients in late first stage of labor.

• The Journal of Pediatrics of Korean Medicine
• /
• v.18 no.1
• /
• pp.273-288
• /
• 2004

Objective: The purpose of this study was to investigate the oriental cause and treatment of the polyhidrosis of hands and feet. Methods: It was studied 47 kinds of Oriental Medical literature for polyhidrosis of hands and feet Results: Polyhidrosis of hands and feet due to lowered superficial resistance brought on by deficiency of qi. Main pathogenesis(病因病機) is the heat in the middle energizer(中焦熱) such as heat in the stomach(胃熱) and the spleen and stomach heat stagnation(脾胃積熱), deficient in Yin and Yang, qi and blood(陰陽氣血), and retention of undigested food(食積) due to improper diet(飮食不能). Treating method(治法) is eliminating dampness and regulating the stomach(淸熱燥瀑和中), invigorating, replenishing spleen qi(補益脾氣), and nourishing the stomach Yin(滋養胃陰). Treating prescription(治方) is presented as Palmultang with Additional Ingredients Rhi.zoma Pinelliae, Pona for principle drug Rhi.zorm Typfwnii Radix Aconiti for adjuvant and messenger drug(八物湯加半夏 茯笭君 白附子 川烏爲在使), Daeshihotang(大柴胡湯), Cheongbisan(淸脾散), Moryeosan(牡蠣散) etc. The external treatments(外用法) are described as ways of washing hand and foot after steaming with boiled Decoction(牡蠣散) of AJurnen(白礬); Radix Puerariae(乾葛), Radix Astragali(黃?); Radix Puerariae(乾葛), Herba Schiwnepetae(荊芥); Radix Saposhnikoviae (防風), 白礬(AIumen). The acupuncture recipes (鍼治療法) are the toninfication(補) of Buryu(KI 7)(復溜) ; Eumgeuk(HT 6)(陰?), tonification(補) methods of Buryu(KI 7)(復溜) ; Gihae(CC 6)(氣海) and reduction(潟) of Hapgok(LI 4)(合谷), the reduction(潟) of Hapgok(LI 4)(合谷), tonification of Buryu(Kl 7)(復溜), reduction(潟) of Jigu(TE 6)(支溝) ; Taechung(LR 3)(太衝) ; Yangneungcheon (GB 34)(陽陸泉). and selection of points of Hapgok(Li 4) (合谷) and Nogung(PC 8)(勞宮). The Tui-na therapies (推拿療法) are removing heat from the stomach meridian(淸胃經O) and so on.

• Radiation Oncology Journal
• /
• v.6 no.2
• /
• pp.289-293
• /
• 1988

Radiation therapy has been used as adjuvant therapy or primary treatment for inoperable, remnant or recurrent cancer. Many authors reported good palliation effect by external irradiation or interstitial therapy, but the report of intracavitary irradiation for recurrent, inoperable rectal cancer is very rare. We experienced a case of recurrent adenocarcinoma of rectum along fistula tract after laparotomy and postoperative radiotherapy who achieved very good palliation by intracavitary irradiation. Even though we have only good palliation without impressive survival improvement in this case, we hope that this technique may achieve good local control In other similar patients.

• Radiation Oncology Journal
• /
• v.12 no.3
• /
• pp.369-376
• /
• 1994

This is a retrospective analysis of 64 patients who was treated with postoperative radiation therapy after radical hysterectomy and bilateral pelvic lymphadenectomy (53 patients) or total abdominal hysterectomy(11 patients) for uterine cervix cancer between May 1980 and September 1991 at the Department of Radiation Oncology, Kyung Hee University Hospital. Most patients were FIGO IB (31 Patients) and IIA (25 patients), and median period of follow-up was 5.1 years. Of these patients,24 received adjuvant whole pelvis irradiation of 6000 cGy and 40 received 5000-5500 cGy whole pelvis irradiation and/or intracavitary radiation (7 Patients). The actuarial overall and relapse free 5 year survival rate were $71.0\%$, $68.3\%$ respectively. The survival rates by stage were $79.1\%$ in stage I, and $61.2\%$ in stage II. Treatment failure was noted in 18 of 64 patients ($28.1\%$), Iocoregional failure in 8 ($12.5\%$), distant metastasis in 8 ($12.5\%$), paraaortic node metastasis in 1 and one patient and concurrent locoregional and distant metastasis. The univariate analysis of prognostic factors affecting to overall survival rate represented lymph node status, the number and site of metastatic lymph node, parametrial invasion, the thichness of cervical wall invasion, and size of cancer mass. Histology, vessel invasion, endometrial extension, hemoglobin level. resection margin status, age, radiation dose were not significant prognostic factors. Complication relating to operation and postoperative radiation were variable according to radiation therapy method: 6000 cGy RT group 8/24($33.3\%$), 5000-5500 cGy+ICR 3/7 ($42.9\%$), 5000-5500 cGy external RT only group 3/33 ($9.1\%$). In conclusion, the results suggest that postoperative radiotherapy is necessary in high risk patients for locoregional control and improving survival rate, and higher dose does not improve results but only increases complication.

• The Korean Journal of Pain
• /
• v.26 no.4
• /
• pp.336-346
• /
• 2013

Intrathecal drug delivery is an effective and safe option for the treatment of chronic pathology refractory to conventional pain therapies. Typical intrathecal administered drugs are opioids, baclofen, local anesthetics and adjuvant medications. Although knowledge about mechanisms of action of intrathecal drugs are every day more clear many doubt remain respect the correct location of intrathecal catheter in order to achieve the best therapeutic result. We analyze the factors that can affect drug distribution within the cerebrospinal fluid. Three categories of variables were identified: drug features, cerebrospinal fluid (CSF) dynamics and patients features. First category includes physicochemical properties and pharmacological features of intrathecal administered drugs with special attention to drug lipophilicity. In the second category, the variables in CSF flow, are considered that can modify the drug distribution within the CSF with special attention to the new theories of liquoral circulation. Last category try to explain inter-individual difference in baclofen response with difference that are specific for each patients such as the anatomical area to treat, patient posture or reaction to inflammatory stimulus. We conclude that a comprehensive evaluation of the patients, including imaging techniques to study the anatomy and physiology of intrathecal environment and CSF dynamics, could become essential in the future to the purpose of optimize the clinical outcome of intrathecal therapy.

• The Journal of Korean Orthopaedic Ultrasound Society
• /
• v.1 no.1
• /
• pp.6-9
• /
• 2008

Purpose: To investigate the effectiveness of injection therapy in the treatment of subacromial bursitis. Materials and Methods: A total of 38 patients with sonographic confirmation of subacromial bursitis were recruited into this study. The shoulder abduction range of motion and visual analog scale (VAS) were compared before injections and 3 wks after the completion of injections. Results: The shoulder range of abduction before injection was $77.89{\pm}14.17$ degrees and improved to $148.68{\pm}13.39$ degrees 3 wks after the injection treatments (P<0.05). VAS before injection was $6.8{\pm}1.4$ and improved to $1.4{\pm}0.8$ 3 wks after the injection treatments (P<0.05). Conclusions: Ultrasound may be used as an adjuvant tool in guiding the needle accurately into the inflamed subacromial bursa. The ultrasound-guided injection technique can result in significant improvement in shoulder abduction range of motion in treating patients with subacromial bursitis.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.23
• /
• pp.10171-10174
• /
• 2015

Background: The purpose of this study was to determine the prognostic significance of the maximum standardized uptake value (SUVmax) on F-18-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients undergoing surgical treatment for non-small cell lung cancer. Materials and Methods: Seventy-eight consecutive patients (58 with adenocarcinomas, 20 with squamous cell carcinomas) treated with potentially curative surgery were retrospectively reviewed. Results: The SUVmax was significantly higher in the patients with recurrent than with non-recurrent adenocarcinoma (p<0.01). However, among the patients with squamous cell carcinoma, there were no differences with or without recurrence (p=0.69). Multivariate analysis indicated that the SUVmax of adenocarcinoma lesions was a significant predictor of disease-free survival (p=0.04). In addition, an SUVmax of 6.19, the cut-off point based on ROC curve analysis of the patients with pathological IB or more advanced stage adenocarcinomas, was found to be a significant predictor of disease-free survival (p<0.01). Conclusions: SUVmax is a useful predictor of disease-free survival in patients with resected adenocarcinoma, but not squamous cell carcinoma. Patients with adenocarcinoma exhibiting an SUVmax above 6.19 are candidates for more intensive adjuvant therapy.